Premium
Effect of angiotensin converting enzyme inhibitor on chronic ischemic patients
Author(s) -
Kawakami Noriaki,
Yamashita Tetsuo,
Nakano Shegeki,
Ishihara Nideyuki,
Kitahara Tetsuhiro,
Nakashima Kazuya,
Kashiwagi Shiro,
Ito Haruhide
Publication year - 1996
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1996.tb00560.x
Subject(s) - cilazapril , medicine , acetazolamide , cerebral blood flow , ace inhibitor , angiotensin converting enzyme , cardiology , cerebral arteries , blood pressure
Most of patients with cerebrovascular diseases are associated with hyper‐tension. Hypertension induces progressive atheromatous changes in cerebral arteries, and often causes steno‐occlusive lesions of cerebral arteries. Angiotensin converting enzyme (ACE) inhibitor cilazapril is one of the antihypertensive drugs. It was reported that cilazapril improved resting cerebral blood flow (CBF) and cerebrovascular reserve capacity (CRC) in experimental studies. In this clinical study, the authors investigated whether long‐term treatment with cilazapril could improve CBF and CRC in patients with steno‐occlusive lesions of the major cerebral arterial trunk, measured by stable xenon computerized tomography (Xe‐CT) with acetazolamide challenge. On the other hand, CBF and CRC in the calcium blocker‐treated patients were measured in the same way. CBF did not change after long‐term treatment with both cilazapril and calcium blocker. In the cilazapril‐treated group, CRC was increased significantly (p < 0.05). However, CRC did not change in the calcium blocker‐treated group. It was recognized that long‐term treatment with cilazapril did not decrease CBF and improved CRC in patients with occlusive lesions of the major cerebral arterial trunk.